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At a glance commentary 
Scientific knowledge on the subject 
In critically ill hematology patients, identifying the cause of the acute illness while providing 
life-supporting interventions is the cornerstone of the initial management. PCR panels for the 
rapid detection of viruses are now available. However, the clinical significance of positive 
PCR results on upper respiratory tract samples remains unclear.  
 
What this study adds to the field 
Among critically ill hematology patients, one in six overall and one in four with acute 
respiratory failure (ARF) had a virus identified in a nasal swab at ICU admission. Presence 
of a virus was associated with lymphoproliferative disorders, hematopoietic stem cell 
transplantation, and treatment with steroids or other immunosuppressants. The most 
common viruses were rhinovirus/enterovirus (56.4%) and influenza/parainfluenza 
(PIV)/respiratory syncytial viruses (RSV) (30.7%). Virus detection was associated with 
higher ICU mortality, and this association was strongest for influenza/PIV/RSV. In patients 
with ARF, detection of any respiratory virus independently predicted ICU mortality. 
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Abbreviations  
 
95%CI, 95% confidence interval 
ARF, acute respiratory failure 
CT, computed tomography 
Grrr-OH, Groupe de recherche respiratoire en réanimation en Onco-Hématologie, a task 
force working on critical respiratory diseases in patients with cancer or hematological 
malignancies 
HM, hematological malignancies 
hMPV, human metapneumovirus 
HSCT, hematopoietic stem-cell transplant 
ICU, intensive care unit 
IPA, invasive pulmonary aspergillosis 
OR, odds ratio 
PCR, polymerase chain reaction  
PIV, parainfluenza virus 
RRT, renal replacement therapy 
RSV, respiratory syncytial virus 
SOFA, Sequential Organ Failure Assessment 
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 ABSTRACT 
Rationale: Noninvasive diagnostic multiplex molecular tests may enable the early 
identification and treatment of viral infections in critically ill immunocompromised patients. 
Objectives: To assess the association between viral detection in nasopharyngeal swabs and 
ICU mortality in critically ill hematology patients. 
Methods: Post-hoc analysis of a prospective cohort of critically ill hematology patients 
admitted to 17 ICUs. Nasal swabs sampled and frozen at ICU admission were tested using a 
multiplex PCR assay. Predictors of ICU mortality and assay positivity were identified. 
Measurements and Main Results: Of the 747 patients (447 with acute respiratory failure 
[ARF]), 21.3% had a virus detected (56.4% rhinovirus/enterovirus and 30.7% 
influenza/parainfluenza [PIV]/respiratory syncytial viruses [RSV]). Overall ICU and hospital 
mortality rates were 26% and 37%, respectively. Assay positivity was associated with 
lymphoproliferative disorders, hematopoietic stem cell transplantation, treatment with 
steroids or other immunosuppressants, ARF (25.5% vs. 16.3%, P=0.004), and death in the 
ICU (28.9% vs. 19.3%, P=0.008). The association with ICU mortality was significant for all 
viruses and was strongest for influenza/PIV/RSV. In patients with ARF, detection of any 
respiratory virus was independently associated with ICU mortality (odds ratio, 2.07; 95% 
confidence interval, 1.22-3.50).  
Conclusions: Respiratory virus detection in the upper airway by multiplex PCR assay is 
common in critically ill hematology patients. In patients with ARF, respiratory virus 
detection was independently associated with ICU mortality. Multiplex PCR assay may prove 
helpful for the risk stratification of hematology patients with ARF. Studies to understand 
whether respiratory tract viruses play a causal role in outcomes are warranted.  
Abstract word count: 248 
 
Keywords: Bone marrow transplantation, neutropenia, oxygen, influenza, parainfluenza 
virus, respiratory syncytial virus, mechanical ventilation, multiplex PCR 
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 INTRODUCTION  
Among patients with hematological malignancies (HM), up to 40% experience acute 
respiratory failure (ARF), for which the risk factors include prolonged neutropenia, complex 
immune deficiencies, and drug-related pulmonary toxicity (1–5). The causes of lung disease 
vary with the nature of underlying malignancy, level of immunosuppression, and treatment 
intensity. Early identification of the cause of ARF is associated with improved outcomes (6–
8). Current diagnostic strategies combine semi-invasive tests (fiberoptic bronchoscopy with 
bronchoalveolar lavage [BAL], minimally invasive computed tomography [CT]-guided 
biopsies) with noninvasive PCR assays on sputum, nasopharyngeal aspirates, and nasal 
swabs. This combined strategy can be expected to identify the cause in about 80% of 
patients (9–11). Hospital mortality, which can reach 50%, is highest when the cause of ARF 
remains unknown (8, 12–14). 
Whereas up to 40% of patients with hematological malignancies have one or more 
viruses detected in their respiratory samples, viruses, mainly diagnosed with the 
collection of upper respiratory tract samples, are much less considered than other 
pathogens such bacteria or Aspergillus as likely cause of ARF (12–15). A positive 
virus PCR test on nasopharyngeal aspirates or nasal swabs may reflect either upper or 
lower respiratory tract infection, the clinical consequences of which can differ 
substantially. However, a positive test may also indicate asymptomatic carriage, 
perhaps with an increased viral burden due to worsening immunosuppression, and 
with or without an impact on mucosal function and/or the local flora. When the virus 
is clinically relevant, as seen during H1N1 epidemics, its rapid detection can help to 
identify patients at risk for respiratory deterioration, determine that isolation and 
preventive measures are needed, and guide early antiviral therapy (19, 20).  
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 Multiplex assays on bronchoalveolar lavage fluid or nasal secretions are effective in 
detecting a wide range of pathogens (21–23), including several viruses known to cause 
pneumonia (e.g., influenza virus, respiratory syncytial virus, parainfluenza virus, human 
metapneumovirus) and others whose potential for causing lower respiratory tract disease is 
unclear (e.g., rhinovirus, coronavirus) (24, 25). Thus, whether the detection of viruses in 
respiratory samples has diagnostic, therapeutic, and/or prognostic relevance is unclear. 
The objective of this study was to assess the clinical relevance of a positive PCR 
assay for viruses on respiratory samples of critically ill hematology patients with or without 
ARF. We retrospectively assessed prospectively collected nasal swabs using a multiplex 
assay and compared patients with and without positive results, notably regarding the 
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 PATIENTS AND METHODS 
Patients 
We performed a post-hoc analysis of data from a prospective multicenter cohort 
study of 1011 critically ill patients with HM admitted to 17 ICUs between January, 1, 2010, 
to May, 1, 2011(14). The study was approved by the appropriate ethics committees. All 
patients/relatives gave written informed consent to study participation.  
Data collection 
In each center, an investigator used a standardized electronic case-report form to 
prospectively collect the study data. The Sequential Organ Failure Assessment (SOFA) score 
was computed at admission. ARF was defined as oxygen saturation <90% or PaO2 <60 
mmHg on room air combined with a respiratory rate >30/min and/or clinical signs of 
respiratory distress (14, 26). A comprehensive diagnostic assessment was performed 
including a physical examination and CT followed by bronchoscopy and BAL and/or 
noninvasive diagnostic tests (27, 11). Etiological diagnoses were made by consensus among 
the managing physicians (intensivists, hematologists, and consultants). Patients with ARF 
were classified into four diagnostic categories (8) (infectious pneumonia as defined by a 
clinically or microbiologically documented lower respiratory tract infection; non-infectious 
lung involvement; opportunistic infection; and undetermined diagnosis). 
 
Molecular assay for respiratory virus detection  
Nasopharyngeal flocked swabs were collected at admission in 3 mL of Universal 
Transport Medium (UTM) (Copan Diagnostics Inc, Murrieta, CA) in patients admitted on 
weekdays and stored at -80°C until testing. For the present study, a multiplex molecular 
assay (ePlex® Respiratory Pathogen Panel, GenMark Diagnostics Inc., Carlsbad, CA) was 
performed according to the manufacturer’s instructions. This assay tests for 20 respiratory 
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 viruses (influenza viruses A–H1, A-H1N1, A-H3, and B; respiratory syncytial viruses [RSV] 
A and B; parainfluenza viruses [PIV] types 1, 2, 3, and 4; human metapneumovirus [hMPV]; 
rhinovirus and/or enterovirus; coronaviruses 229E, HKU1, NL63, OC43, and MERS; 
adenovirus, and bocavirus) and for four bacteria (Bordetella pertussis, Chlamydophila 
pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae).  
Samples positive for rhinovirus/enterovirus, underwent sequencing the VP4/VP2 
coding region as previously described (28). PCR products were sequenced on an ABI 3100 
DNA Sequencer (Applied Biosystems, Life Technologies, Carlsbad, CA). Alignment and 
sequence comparison to NCBI published sequences were carried out using the Geneious 
8.0.5 software (Biomatters, Auckland, NZ) and MEGA version 7 (CEMI, Tempe, AZ).  
 
Statistical analysis  
The primary outcome was the rate of respiratory viral infections in patients with ARF 
and those without. Secondary outcomes were the association between respiratory viral 
infections and death in ICU and risk factors of death in patients with ARF. Several groups 
were compared: patients with respiratory viral infections and those without, patients with 
and without ARF. ePlex® positive status was defined as the detection of at least one 
pathogen by the ePlex® respiratory panel 
Categorical variables were described as numbers and percentages and quantitative 
variables as medians (25th-75th quartiles). Between-group comparisons were with Fisher's 
exact test for categorical variables and the Wilcoxon rank sum test for quantitative variables.  
Factors associated with ICU mortality were assessed by logistic regression. In 
addition to the ePlex® assay result, the model included both the variables associated with the 
outcome in the original study (14) and the clinically meaningful variables (underlying 
malignancy, poor ECOG performance status, Charlson comorbidity index, allogeneic 
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 hematopoietic stem cell transplant [HSCT] recipient, complete or partial remission, time 
from hospital to ICU admission <24 h, SOFA score, organ infiltration by the malignancy, 
and invasive pulmonary aspergillosis). Variable selection was with a backward stepwise 
procedure with a stopping rule based on the Akaike criterion. Odds ratios (ORs) of variable 
effects in the final model are reported with their 95% confidence intervals (95%CIs). 
Goodness-of-fit of the final model was checked using the le Cessie–van Houwelingen test. 
All tests were two-sided at the 0.05 level. Analyses were performed using the R statistical 
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 RESULTS  
 
Patients 
Among the 1011 critically ill hematology patients, 747 had nasal swabs tested by 
ePlex® (Figure 1). None of the collected variables were significantly different between the 
747 included patients and the 264 patients without nasal swabs.  
Table 1 reports the patient characteristics at admission. Median age was 60 [49;70] 
years. Almost half the patients had a lymphoid malignancy and one-third had myeloid 
malignancies (Table 1). The HM was newly diagnosed in 280 (37.5%) patients and in partial 
or complete remission in 174 (23.3%) patients. There were 190 (25.4%) HSCT recipients. In 
the previous month, 423 (56.6%) patients had received corticosteroids or other 
immunosuppressants. The main reason for ICU admission was ARF (n=447, 59.8%). Shock 
was present in 316 (42.4%) patients. Invasive mechanical ventilation was provided to 351 
(33.6%) patients and vasoactive drugs to 370 (49.5%) patients. ICU and hospital mortality 
rates were 26% and 37.1%, respectively. 
 
Results of molecular viral detection 
The ePlex® Respiratory Pathogen Panel identified 179 pathogens in 163 (21.8%) 
patients, including 149 (83.2%) with a single pathogen and 14 with more than one pathogen 
(12 with two and 2 with three pathogens). Four samples were positive for Legionella 
pneumophila. All other samples were positive for respiratory viruses (Table 2).  
 The most prevalent virus was rhinovirus/enterovirus (n=92/163, 56.4%), followed by 
coronavirus (n=22, 13.5%), influenza virus (n=20, 12.3%), RSV (n=18, 11.0%), and PIV 
(n=12, 7.4%). Adenovirus (n=5, 3.1%), hMPV (n=4, 2.5%), and bocavirus (n=2, 1.2%) were 
less frequently detected. The virus type was determined for 71 of the 92 
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 rhinovirus/enterovirus-positive samples, with the following results: rhinovirus species A, 
n=35; rhinovirus species B, n=9; rhinovirus species C, n=24; and enterovirus D68, n=3. Of 
the respiratory viruses, 66.8% were detected during the winter and spring. There was a 
seasonal variation of samples positive for respiratory viruses (Table 3). Influenza and RSV 
were significantly more detected during winter (p<0.0001) while rhinoviruses were slightly 
more frequent during summer and autumn (p=0.02) (Table S1). 
Overall, respiratory viruses were more frequently detected in patients with ARF 
(25.5% vs. 16.3%, P=0.004) and in patients who died in the ICU (28.9% vs. 19.3%, 
P=0.008) (Table 2). Influenza-like viruses (influenza/PIV/RSV) were particularly prevalent 
in patients with ARF (10.1% vs. 1.7%, P<0.0001) and in patients who died in the ICU 
(11.3% vs 5.1%, P=0.004). Rhinovirus/enterovirus, coronavirus, adenovirus, hMPV, and 
bocavirus were found in similar proportions of patients across subgroups with vs. without 
ARF and in ICU survivors vs. nonsurvivors. Viral-viral or viral-bacterial coinfections were 
not associated with ARF but were more prevalent in patients who died in the ICU (5.7 vs. 
0.5%, P<0.0001). 
 
Characteristics and outcomes of patients with a positive viral assay 
As shown in Table 3, neither SOFA score on day 1 nor presence of shock differed 
between patients with vs. without detected viruses. Respiratory viruses were more frequently 
detected in HSCT recipients than in other patients (42.9% vs. 20.7%, P<0.0001) and in 
patients on steroids (46% vs. 36%, P=0.026) or other immunosuppressants (23.0% vs. 
16.6%, P=0.043). Presence of respiratory symptoms on day 1 (including fever, cough, 
dyspnea, chest pain, wheezing, rhinitis, and/or myalgia) with or without signs of ARF was 
significantly more common in patients with a positive ePlex® (85.9% vs. 72.2%, P=0.0005). 
However, 23 (14.1%) patients with a positive ePlex® had no respiratory symptoms on day 1 
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 but none had any Influenza-like virus (Table S2). In patients with no respiratory symptoms, 
there was no difference of mortality in ICU between patients with a positive ePlex® result 
and those with a negative ePlex® result (Table S3). 
Overall there was no difference in of the presence of rhinovirus in patients who died 
in ICU compare to those who were discharged alive (Table 2). However, death was observed 
more frequently in patients with a detection of rhinovirus Species C (11/24, 45.8%) than in 
those with a detection of rhinovirus Species A or B (9/44, in 20.5%) (Fisher exact test, 
p.value=0.049) (Table 2). In addition, within the cohort of patients with ARF (447 patients), 
we observed a higher proportion of death among patients with Rhinovirus species C (9/17, 
52.9%) than among patients with Rhinovirus Species A or B (p.value=0.049). 
Noninvasive ventilation was used significantly more often in virus-positive patients 
(39.9% vs. 29.6%, P=0.017). For invasive mechanical ventilation, the difference was nearly 
significant (54.0% vs. 45.0%, P=0.053). ICU mortality was higher in virus-positive patients 
(34.3% vs. 23.6%, P=0.008). No significant difference was found for hospital mortality 
(41.1% vs. 36%, P=0.27) or mortality on day 90 (47.7% vs. 45.2%, P=0.69). There were no 
differences in the use of vasoactive drugs or renal replacement therapy (RRT) or in the rate 
of ICU-acquired infections (Table 3).  
 
Characteristics and outcomes associated with respiratory virus detection in patients 
with acute respiratory failure (ARF) 
In the group with ARF (Table 4), the clinical presentation at admission was similar in 
the virus-positive and virus-negative patients. Although there was no difference in maximal 
oxygen flow in patients breathing spontaneously, the PaO2/FiO2 ratio tended to be lower in 
the virus-positive patients who required mechanical ventilation (118 [71-206] vs. 150 [96-
258], P=0.052).  
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 The chest radiograph was more often normal in the virus-positive patients (17.9% vs. 
9.9%, P=0.039). In patients who underwent CT of the chest, the only finding that differed 
between groups was pleural effusion, which was significantly less common in the virus-
positive group (12.3% vs. 24.8%, P=0.009).  
Among virus-positive patients with ARF, 27.2% had clinically or microbiologically 
documented bacterial pneumonia. Documented bacterial pneumonia was less common 
among virus-positive than virus-negative patients. Invasive pulmonary aspergillosis (IPA) 
was diagnosed in 9.7% of virus-positive and 3.9% of virus-negative patients (Table 4).  
The use of antibiotics and of life-supporting interventions (mechanical ventilation, 
vasoactive drugs, RRT) in the group with ARF was not significantly different between virus-
positive and virus-negative patients. As in the overall population, a positive viral assay was 
associated with higher ICU mortality in the ARF group (40.3% vs. 24.3%, P=0.002). The 
hospital and day-90 mortality rates were not different between the virus-positive and virus-
negative groups. Changes in the daily SOFA score from admission to day 7 were not 
different between virus-positive and virus-negative patients (Figure S1) and or patients with 
vs. without detection of influenza-like viruses (Figure S1).  
By multivariable analysis, detection of a virus was independently associated with 
ICU mortality (OR, 2.07; 95%CI, 1.22-3.50, P=0.006). Other independent risk factors for 
ICU mortality were IPA (OR, 2.43; 95%CI, 1.23-4.81; P=0.01), poor ECOG performance 
status (OR, 1.89; 95%CI, 1.09-3.27; P=0.024), and SOFA score >7 at admission (OR, 1.27; 
95%CI, 1.20-1.36; P<0.001) (Figure 2, Table S4). Steroid therapy was not associated with a 
worse prognosis in patients with ARF (Table S5 and S6). 
 
Impact of influenza-like viruses 
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 In the overall population, patients with influenza-like viruses had higher ICU 
mortality (44.4% vs. 24.5%, P=0.002). They more often presented with ARF (88.9% vs. 
57.6%, P<0.0001) and more often required invasive or noninvasive mechanical ventilation 
(75.9% vs. 58.7%, P=0.014) (Figure 3).  
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 DISCUSSION 
In this study we assessed the clinical relevance of a positive multiplex PCR assay for 
viruses on respiratory samples of critically ill hematology patients. We analyzed 
nasopharyngeal swabs collected at admission to ICU in patients with or without respiratory 
symptoms, enabling to better estimate the clinical significance of detection of respiratory 
viruses. In this large multicenter prospective cohort study of 747 critically ill patients with 
HMs, respiratory virus detection was associated with both ARF and higher ICU mortality. 
Both associations were largely due to the influenza-like viruses (Influenza/PIV/RSV). 
Species C of rhinovirus was associated with a higher proportion of death among patients in 
the whole cohort and in patients with ARF than rhinovirus Species A or B.  
Although there is no recommendation for routine molecular testing, multiplex PCR is 
widely used to identify the cause of ARF, in combination with clinical, radiological, and 
standard microbiological evaluations. However, due to the high sensitivity of molecular 
assays and high prevalence of asymptomatic carriage of respiratory viruses, a positive 
molecular assay is not proof that the detected virus is causing disease. Immunosuppression 
may increase the burden of viruses not conventionally associated with significant disease, so 
that a positive PCR assay may be merely a marker for poor immune function (29). In 
addition, presence of a virus can alter the bacterial flora in the upper respiratory tract, an 
effect that might in turn promote bacterial pneumonia (30). Finally, respiratory viruses may 
enhance bacterial adhesion to, and invasion of, the respiratory mucosa (30). In studies of 
patients with community-acquired bacterial pneumonia, viral coinfection was associated 
with a worse prognosis (31–33). Thus, the effects of respiratory viruses are complex, and 
whether virus detection by PCR in an upper airway sample from a critically ill hematology 
patient should lead to antiviral treatment is unclear. As a first step toward obtaining 
clarification, we routinely sampled the upper airway of unselected, critically ill, hematology 
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 patients at ICU admission, regardless of whether respiratory symptoms were present. The 
results were analyzed at a distance from ICU admission. Presence of a virus in this setting 
might indicate a direct contribution of the virus to the critical illness (e.g., viral pneumonia), 
an indirect contribution of the virus via alterations in respiratory tract ecology and mucosal 
function, asymptomatic carriage with no role for the virus in the symptoms but a possible 
viral load increase due to immunosuppression, or a false-positive test result. Antiviral 
treatment would be in order only in the first two cases. The lack of lower respiratory tract 
samples, such as broncho-alveolar lavages, hampered direct evaluation of the impact on 
respiratory tract ecology and mucosal function. We sought to determine whether any of our 
findings were in favor of a direct or indirect causal role for detected viruses in the clinical 
illness. 
Half the pathogens detected in our patients were rhinovirus/enterovirus. With 
coronaviruses, rhinoviruses are the leading cause of rhinitis,  and less often cause pneumonia 
(29, 34–38) . The higher prevalence of these viruses than previously reported in hematology 
patients may be due to the very high sensitivity of ePlex®, particularly for rhinovirus species 
C. Several studies have recently shown that rhinovirus could contribute to severe lower 
respiratory tract infections in immunocompromised hosts (39–41). Severe rhinovirus 
infections presented with similar clinical features and same overall mortality than Influenza-
like viruses In our study including patients with or without respiratory symptoms at 
admission, the prevalence of rhinovirus did not differ neither between patients with ARF and 
those nor between who died in ICU or were alive at ICU discharge. Rhinovirus is classified 
into three species A, B and C. Some studies reported that species C was associated with 
more severe infections, with more frequent lower respiratory tract infections (42, 43) but 
some others found no difference between the three species (41, 44). In addition recent 
studies suggest that Species C targets specifically ciliated epithelial cells while species A and 
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 B may infect non epithelial cells (45). The analysis of rhinovirus as one group only may thus 
be not appropriate. In this series, we found that Species C was associated with a higher 
mortality in the whole cohort and in patients with ARF compare to species A and B. These 
results suggest that the impact of rhinovirus infection may differ according to the species. 
This observation needs to be confirmed in other studies and deserves further research to 
understand underlying mechanisms. 
Other viruses were detected in similar proportions of patients after adjustment for age 
and season. In keeping with this fact, the higher frequencies of ARF and ICU death in the 
virus-positive group was largely ascribable to the patients with influenza-like viruses 
(Influenza/PIV/RSV, hMPV). Others have reported similar results (46).  
Thus, in agreement with other studies, our results emphasize the need for specific 
antiviral therapy in critically ill patients with hematological malignancies when a molecular 
multiplex assay is positive for influenza in an upper respiratory tract sample Early 
oseltamivir therapy improves the outcome in critically ill patients with influenza: a 
propensity analysis (47–49). 
Among patients with ARF, respiratory virus detection was a predictor of ICU 
mortality that was nearly as strong as IPA. While IPA is a well-known risk factor for 
mortality in critically ill hematology patients, our study is the first to report that respiratory 
viruses were also independently associated with ICU mortality. Three hypotheses may 
explain this association. One involves a double hit, in which patients developing a 
respiratory virus infection shortly before ICU admission would be then more vulnerable to 
bacterial infection, leading to a critical illness. The lower PaO2/FiO2 ratio in virus-positive 
patients may seem to support this possibility, but the more often normal chest radiographs 
and similar SOFA scores over the first week compared to virus-negative patients do not. 
Another hypothesis is that bacterial or fungal respiratory tract infection would promote viral 
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 infection via weakening of the local defense mechanisms (50). The viral infection may then 
worsen the initial disease. A recent work suggested that the alteration of microbial ecology 
after antibiotic exposure was associated with a higher risk of viral lower respiratory tract 
infection with following PIV, RSV, and hMPV (51). Viral infections and invasive fungal 
infections share common risk factors (52–54) that are common in hematology patients, such 
as allogeneic HSCT and treatment with corticosteroids or other immunosuppressants. 
Finally, a positive viral assay might be a marker for immunosuppression or other 
vulnerability factors.  
The contribution of PCR assays to the etiological diagnosis of ARF is probably 
modest. Nevertheless, our results suggest that rapid routine multiplex molecular testing for 
upper respiratory tract viruses in hematology patients admitted to the ICU may contribute to 
identify patients at highest risk for mortality. Such finding could be delineated into different 
ways. Namely, based on a positive virus in the nasal swab, these high risk patients should be 
admitted earlier to the ICU/HDU to undergo noninvasive management and close monitoring. 
Moreover, these patients should be considered as more severely immunocompromised and 
may also be eligible for preventive strategies such as antifungal prophylaxis. However, for 
such practices to be implemented, we need to validate these concepts in future observational 
and interventional studies. Although antiviral drugs available to treat respiratory viral 
infections are currently limited to influenza, our results identify patients who should benefit 
to new antiviral drugs or included in trials evaluating treatments under development. 
Regarding the association with IPA, antifungal treatment might be in order in 
patients with ARF who do not respond promptly to antibacterial treatment and whose 
multiplex test for upper respiratory tract viruses is positive. In patients whose test is positive 
for influenza, early antiviral treatment and preventive measures to limit nosocomial 
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 transmission may be warranted. Our results suggest that critically ill hematology patients 
may be a population of interest for evaluating new drugs targeting RSV and PIV.  
This study has several limitations. For feasibility reasons, 264 patients (26.1% of the 
initial cohort) admitted on weekends were not included. However, the baseline 
characteristics and ICU mortality of these 264 patients were not significantly different from 
those in the included patients. We had no information on the occurrence of hospital-acquired 
pneumonia or ventilator-associated pneumonia during the ICU stay. The study design does 
not allow conclusions about the nature of the link between the detection of viruses and ICU 
mortality. Indeed, although mortality related to infection is usually high in this setting, 
ascription of death to infection was not assessed due to the level of uncertainty. Future 
studies involving the collection of biomarkers and specific patient phenotypes in this 
hematology population are warranted. Also, lower respiratory tract samples and autopsy 
studies of the lung lesions might shed light on the role for viruses versus other causes of lung 
involvement, document undetected pathogens, and provide information on resident and 
recruited alveolar cells and their relationship to severity and mortality.  
In conclusion, a respiratory virus was detected in the upper airway of one in six 
critically ill hematology patients overall and of one in four of those with ARF. Virus 
detection was more common in patients who died in the ICU, and this association was 
chiefly due to influenza/PIV/RSV. In patients with ARF, however, detection of any 
respiratory virus was an independent predictor of ICU mortality. Routine PCR screening of 
upper airway samples in critically ill hematology patients may help to identify patients at 
high risk for respiratory deterioration and mortality. However, whether these patients are 
potential candidates for immunomodulation, new antiviral treatments, early ICU admission, 
or antifungal therapy remains unclear. These results encourage a trial of routine screening 
for respiratory viral detection by PCR at ICU admission in hematology patients. Therapeutic 
Page 20 of 48 AJRCCM Articles in Press. Published on 19-September-2018 as 10.1164/rccm.201804-0681OC 
 Copyright © 2018 by the American Thoracic Society 
 indications must be appraised. This high-risk population may be a good target for evaluating 
the antiviral treatments that are currently being developed.   
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 FIGURE LEGENDS 
Figure 1 
Patient flow diagram 
* Reasons for not sampling or testing patients included weekend admissions (n=241) and 
unusable samples (n=23). 
Abbreviations: ARF, acute respiratory failure; ICU, intensive care unit.  
 
Figure 2 
Multivariable analysis for factors independently associated with ICU mortality among 
patients with ARF 
Abbreviations: ICU, intensive care unit; ARF, acute respiratory failure; SOFA, Sequential 
Organ Failure Assessment. 
 
Figure 3  
Associations linking influenza-like virus infections or infections with other viruses to 
ARF and death or mechanical ventilation 
Influenza-like viruses include influenza viruses, parainfluenza viruses, respiratory syncytial 
viruses and human metapneumovirus. Other viruses include rhinovirus and coronavirus. 
Abbreviations: MV, mechanical ventilation; ARF, acute respiratory failure. 
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 Table 1 
Baseline characteristics at ICU admission 
The data are numbers and percentages unless otherwise specified. 
* Some patients were admitted for more than one reason. 
Abbreviations: ICU, intensive care unit; IQR, interquartile range (25th and 75th quartiles) 





 results according to presence or absence of ARF and ICU 
mortality 
Categorical data are reported as numbers and percentages. 
* Viral-viral and viral-bacterial co-infections were considered. 
Abbreviations: ARF, acute respiratory failure; ICU, intensive care unit; HRV, human 
rhinovirus; EV, enterovirus; HRV-A, human rhinovirus species A; HRV-B, human 
rhinovirus species B; HRV-C, human rhinovirus species C;  FLU, influenza virus; RSV, 
respiratory syncytial virus; PIV, parainfluenza virus; hMPV, human metapneumovirus 
 
Table 3 
Comparison of patients with a positive versus a negative ePlex
®
 result 
Quantitative data are reported as median [25th and 75th quartiles] and categorical data as 
numbers and percentages. 
Abbreviations: IQR, interquartile range; HSCT, hematopoietic stem cell transplantation; 
ICU, intensive care unit; ARF, acute respiratory failure 
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 Table 4 
Among patients with acute respiratory failure, comparison of patients with a positive 
versus a negative ePlex
®
 result 
Quantitative data are reported as median [25th and 75th quartiles] and categorical data as 
numbers and percentages. 
Abbreviations: ARF, acute respiratory failure; IQR, interquartile range; PaO2/FiO2, ratio of 
partial pressure of arterial oxygen over fraction of inspired oxygen; SOFA, Sequential Organ 
Failure Assessment; CT, computed tomography; ICU, intensive care unit 
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 Table 1 
 
Variable N  % 
Age, years, median [IQR]       60 [49;70] 
Male gender 454 60.8 
Chronic respiratory insufficiency 189 25.3 
Charlson comorbidity index, median [IQR]         4 [3;6] 
Poor performance status (>2) 150 20.1 
Underlying malignancy   
Lymphoid malignancy 367 49.1 
Non-Hodgkin lymphoma 235 31.5 
Chronic lymphocytic leukemia 60 8 
Acute lymphoblastic leukemia 53 7.1 
Hodgkin lymphoma 19 2.5 
Myeloid malignancy 250 33.5 
Acute myeloid leukemia 200 26.8 
Myelodysplastic syndrome 35 4.7 
Chronic myeloid leukemia 15 2 
Other 130 17.4 
Multiple myeloma 96 12.8 
Other hematological malignancy 34 4.6 
Time between diagnosis and ICU admission, days, median [IQR]           174 [6;865] 
Malignancy status at admission   
Newly diagnosed 280 37.5 
Complete or partial remission 174 23.3 
Progression 270 36.2 
Unknown 23 3 
Hematopoietic stem cell transplantation 190 25.5 
Autologous 84 11.3 
Allogeneic 106 14.2 
Corticosteroids in the previous month 284 38.2 
Other immunosuppressants in the previous month 136 18.2 
Time from hospital to ICU admission, days, median [IQR]       4 [1;18] 
Reason for ICU admission *     
Acute respiratory failure 447 59.8 
Shock 316 42.4 
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   Total  ARF  No ARF  P value Patients who 






N (%) N=747  N=447  N=300    N=194  N=553    
Positive ePlex® 163 (21.8) 114 (25.5) 49 (16.3) 0.004 56 (28.9) 107 (19.3) 0.008 
HRV/EV 92  62 (13.9) 30 (10) 0.14 32 (16.5) 60 (10.9) 0.053 
HRV-A 35 22 13  8 27  
HRV-B 9 6 3  1 8  
HRV-C 24 17 7  11 13  
FLU-like 54  48 (10.7) 6 (2.0) <0.0001 24 (12.4) 30 (5.4) 0.002 
FLU 20  20 0  12 8  
RSV 18 15 3  7 11  
PIV  12 10 2  3 9  
HMPV 4 3 1  2 2  
Coronavirus 22  11 (2.5) 11 (3.7) 0.46 9 (4.6) 13 (2.4) 0.17 
Adenovirus 5  2 (0.5) 3 (1) 0.65 1 (0.5) 4 (0.7) 1 
hMPV 4  3 (0.7) 1 (0.3) 0.91 2 (1.0) 2 (0.4) 0.6 
Bocavirus 2  1 (0.2) 1 (0.3) 1 1 (0.5) 1 (0.2) 1 
Co-infections* 14  12 (2.7) 2 (0.7) 0.086 11 (5.7) 3 (0.5) <0.0001 
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 P value 
N (%) - median [IQR]  N=584  N=163    
Baseline characteristics    
Age, years  61 [49;70] 58 [47;67] 0.11 
Underlying malignancy       
Myeloid malignancy  209 (35.8) 41 (25.1) 0.029 
Lymphoid malignancy  280 (47.9) 87 (53.4)  
Other 95 (16.3) 35 (21.5)  
Hematopoietic stem cell transplantation     
No  463 (79.3) 92 (57.1) <0.0001 
Yes, autologous 57 (9.7)  27 (16.8)  
Yes, allogeneic 64 (11.0) 42 (26.1)  
Corticosteroids in the previous month 209 (36.0) 75 (46.0) 0.026 
Other immunosuppressants in the previous 
month 
97 (16.6) 39 (23.9) 0.043 
Season at ICU admission       
Winter 191 (32.7) 72 (44.2) 0.035 
Spring 202 (34.6) 42 (25.8)  
Summer 82 (14.0) 24 (14.7)  
Autumn 109 (18.7) 25 (15.3)  
Reason for ICU admission     
Acute respiratory failure 333 (57.0) 114 (69.9) 0.004 
Shock 245 (42.0) 71 (43.6) 0.79 
Respiratory symptoms on day 1       
Respiratory symptoms with ARF 308 (52.7) 111 (68.1) 0.0005 
Respiratory symptoms without ARF 114 (19.5) 29 (17.8)  
No respiratory symptoms 162 (27.8) 23 (14.1)  
SOFA >7 229 (41.5) 77 (49.7) 0.084 
Interventions and outcomes     
Chemotherapy 164 (28.1) 31 (19.0) 0.025 
Anti-infectious therapies       
Antibacterial therapy 452 (77.9) 137 (84.6) 0.083 
Antifungal therapy 224 (38.4) 63 (38.7) 1.00 
Antiviral therapy 241 (41.3) 81 (49.7) 0.067 
Life-supporting interventions     
Noninvasive ventilation 173 (29.6) 65 (39.9) 0.017 
Mechanical ventilation 263 (45.0) 88 (54.0) 0.053 
Vasoactive drugs 284 (48.6) 86 (52.8) 0.4 
Renal replacement therapy 149 (26.2) 45 (28.1) 0.7 
Outcomes       
Hospital-acquired infection 96 (16.4) 30 (18.4) 0.64 
ICU mortality 138 (23.6) 56 (34.4) 0.008 
Hospital mortality 210 (36.0) 67 (41.1) 0.27 
Overall mortality on day 90 248 (45.2) 73 (47.4) 0.69 
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 Table 4 
 Negative ePlex
® 
  Positive ePlex
®
   P value 
N (%) - median [IQR]  N=333  N=114    
Clinical presentation on day 1       
Respiratory rate (/min) 32 [26;38] 32 [26;36] 0.68 
Temperature (°C)  38.2 [37.3;39.1] 38.3 [37.4;39.2] 0.31 
Cough 122 (36.6) 46 (40.4) 0.64 
Purulent sputum 34 (10.4) 7 (6.3) 0.28 
Myalgia 10 (3.1) 3 (2.7) 1.00 
Rhinorrhea 4 (1.2) 3 (2.7) 0.52 
Chest pain 43 (13.1) 8 (7.2) 0.13 
Maximal oxygen flow (L/min)  8 [4;15] 9 [4;15] 0.91 
PaO2/FiO2 in patients requiring mechanical 
ventilation  
150 [96;258] 118 [71;206] 0.052 
SOFA >7 139 (44.4) 58 (52.3) 0.19 
Chest radiography pattern       
Normal  32 (9.9) 20 (17.9) 0.039 
Alveolar condensations 203 (61.0) 63 (55.3) 0.34 
Interstitial opacities 89 (27.6) 39 (34.8) 0.18 
Nodular opacities 15 (4.6) 1 (0.9) 0.13 
Pleural effusion 86 (26.6) 19 (17.0) 0.054 
Computed tomography     
Normal  5 (1.5) 2 (1.8) 1 
Alveolar condensations 77 (23.1) 23 (20.2) 0.6 
Ground-glass opacities 53 (15.9) 18 (15.8) 1 
Nodular patterns 36 (10.8) 14 (12.3) 0.8 
Pleural effusion 82 (24.8) 14 (12.4) 0.009 
Etiologies of pulmonary involvement      
Infectious      <0.0001 
Clinically documented bacterial infections 52 (15.6) 9 (7.9)  
Microbiologically documented bacterial     
infections 
55 (16.5) 22 (19.3)  
Opportunistic infections      
Invasive pulmonary aspergillosis 13 (3.9) 11 (9.7)  
Pneumocystis jirovecii infections 10 (3) 5 (4.4)  
Noninfectious lung involvement      
Cardiac pulmonary edema 39 (11.7) 14 (12.3)  
Undetermined 48 (14.4) 12 (10.5)  
Interventions and outcomes     
Anti-infectious therapies     
Antibacterial therapy 282 (85.5) 106 (93.0) 0.054 
Antifungal therapy 151 (45.4) 50 (43.9) 0.87 
Antiviral therapy 151 (45.4) 64 (56.1) 0.06 
Life-supporting interventions       
Noninvasive ventilation 144 (43.2) 57 (50) 0.25 
Mechanical ventilation 173 (52.0) 67 (58.8) 0.25 
Vasoactive drugs 174 (52.3) 70 (61.4) 0.11 
Renal replacement therapy 78 (24.2) 32 (28.6) 0.42 
Outcomes     
Hospital-acquired infection 59 (17.7) 21 (18.4) 0.98 
ICU mortality 81 (24.3) 46 (40.4) 0.002 
Hospital mortality 123 (36.9) 52 (45.6) 0.13 
Overall mortality on day 90 146 (46.8) 55 (51.4) 0.48 
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Methods 
Step wise model. 
In the step wise model,  we considered variables already known as prognostic factors 
in the princeps study based on this cohort (Azoulay, E., Mokart, D., Pène, F., Lambert, 
J., Kouatchet, A., Mayaux, J., Vincent, F., Nyunga, M., Bruneel, F., Laisne, L.M. and 
Rabbat, A., 2013. Outcomes of critically ill patients with hematologic malignancies: 
prospective multicenter data from France and Belgium—a groupe de recherche 
respiratoire en reanimation onco-hematologique study. Journal of Clinical Oncology, 
31(22), pp.2810-2818). In practice we considered the following factors: poor ECOG 
performance status (Performance status), Charlson comorbidity index 
(Charlson), allogeneic hematopoietic stem cell transplant [HSCT] recipient 
(Allograft), complete or partial remission (Remission), time from hospital to ICU 
admission <24 h (Time to ICU <24h), SOFA score (SOFA), organ infiltration by the 
malignancy (Organ infiltration), and invasive pulmonary aspergillosis 
(Aspergillus). Admission after cardiac arrest was not considered due to the too 
small number of patients with admission after cardiac arrest in this subcohort. 
Underlying malignancies was added in initial model as immunocompromised patients 
are more susceptible for severe viral infection (Underlying malignancies). 
Nevertheless, this variable was not kept by the variable selection procedure. Variable 
selection was a backward stepwise procedure (backward and forward) with a 
stopping rule based on the Akaike criterion. Please find the complete procedure 
below, that we have added in supplementary data. 
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 The linear predictor considered for the initial logistic model 
was the following: 
ICU death ~ Underlying malignancies + Performance status + 
Charlson + Allograft + Remission + Time to ICU <24h + SOFA + 
Organ infiltration + Aspergillus + Viral detection 
 
The complete selection process is described below. For all 
model the Akaike Criteria (AIC) is given: 
Start:  AIC=420.19 
ICU death ~ Underlying malignancies + Performance status + 
Charlson + Allograft + Remission + Time to ICU <24h + SOFA + 
Organ infiltration + Aspergillus + Viral detection 
                           Df  Deviance AIC 
- Underlying malignancies 2    398.13  418.13 
- Allograft 1    396.20  418.20 
- Organ infiltration 1    396.32  418.32 
- Time to ICU <24h 1  396.41 418.41 
- Remission                 1  396.96 418.96 
<none>                            396.19 420.19 
- Charlson                  1  398.73 420.73 
- Performance status            1  399.37 421.37 
- Aspergillus 1  401.12 423.12 
- Viral detection            1  402.08 424.08 
- SOFA 1  471.05 493.05 
 
Step:  AIC=418.13 
ICU death ~ Performance status + Charlson + Allograft + Remission + 
Time to ICU <24h + SOFA + Organ infiltration + Aspergillus + Viral 
detection 
                           Df Deviance AIC 
- Allograft 1  398.19 416.19 
- Organ infiltration 1    398.34 416.34 
- Time to ICU <24h 1  398.36 416.36 
- Remission 1  398.60 416.60 
<none>                            398.13 418.13 
- Charlson 1  401.20 419.20 
- Performance status 1  401.42 419.42 
- Aspergillus 1  403.12 421.12 
- Viral detection 1  403.92 421.92 
- SOFA 1  472.52 490.52 
 
Step:  AIC=416.19 
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ICU death ~ Performance status + Charlson + Remission + Time to ICU 
<24h + SOFA + Organ infiltration + Aspergillus + Viral detection 
                           Df Deviance AIC 
- Time to ICU <24h 1    398.41 414.41 
- Organ infiltration 1    398.41 414.41 
- Remission 1    398.81 414.81 
<none>                            398.19 416.19 
- Performance status 1  401.42 417.42 
- Charlson 1  401.71 417.71 
- Aspergillus 1  403.13 419.13 
- Viral detection 1  403.92 419.92 
- SOFA 1  472.53 488.53 
 
Step:  AIC=414.41 
ICU death ~ Performance status + Charlson + Remission + SOFA + Organ 
infiltration + Aspergillus + Viral detection 
                           Df Deviance AIC 
- Organ infiltration      1  398.59 412.59 
- Remission 1  399.05 413.05 
<none>   398.41 414.41 
- Charlson 1  401.79 415.79 
- Performance status 1  401.92 415.92 
- Aspergillus 1  403.44 417.44 
- Viral detection 1  404.02 418.02 
- SOFA 1  472.61 486.61 
 
Step:  AIC=412.59 
Icu death ~ Performance status + Charlson + Remission + SOFA + 
Aspergillus + Viral detection 
                           Df Deviance AIC 
- Remission 1  399.27 411.27 
<none>    398.59 412.59 
- Charlson 1  401.98 413.98 
- Performance status 1  402.06 414.06 
- Aspergillus 1  403.50 415.50 
- Viral detection 1  404.09 416.09 
- SOFA 1  472.69 484.69 
 
Step:  AIC=411.27 
Icu death ~ Performance status + Charlson + SOFA + Aspergillus + 
Viral detection 
                           Df Deviance AIC 
<none>   399.27 411.27 
- Performance status 1    402.75 412.75 
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- Charlson 1    402.98 412.98 
- Viral detection 1    404.26 414.26 
- Aspergillus 1    404.43 414.43 
- SOFA 1    473.71 483.71 
 
The coefficient obtained with the final model is: 
Coefficients:       
(Intercept) -3.7521            
Performance status            0.5387 
Charlson        0.1040 
SOFA         0.2411 
Aspergillus   0.8552 
Viral detection Pos 0.6199   
Degrees of Freedom: 419 Total (i.e. Null);  414 Residual 
Null Deviance:     504.4  
Residual Deviance: 399.3  AIC: 411.3 
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Results 
Table S1. Frequencies of Influenza virus, Respiratory Syncitial Virus, and Rhinovirus 
according to the season. 
 Influenza  RSV  Rhinovirus 
Neg Pos  Neg Pos  Neg Pos 
Winter 247 16  247 16  234 29 
Spring 241 3  243 1  223 21 
Summer 106 0  106 0  86 20 
Autumn 133 1  133 1  112 22 
p value
a





Table S2. Pathogens detected by ePlex in in patients with no respiratory.  
 









Legionnella pneumophila-CornavirusOC43-Rhinovirus 1 
Rhinovirus 12 
 
Table S3. ICU mortality in patients with no respiratory symptoms with a positive ePlex 
result or a negative ePlex result.  
 
ICU mortality ePlex negative ePlex positive 
No 131 19 
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Table S4. Multivariable analysis for factors independently associated with ICU mortality 
among all patients admitted to ICU with a ePlex test. 
 
  OR  CI95 CI95 p.value 
   Low High 
Invasive pulmonary aspergillosis 2.36 1.23 4.51 0.0094 
Positive Eplex 1.64 1.06 2.54 0.026 
Poor performance status 2.30 1.50 3.53 0.00014 
SOFA score at admission 1.28 1.22 1.34 3.2e-23 
Charlson comorbidity index 1.14 1.05 1.24 0.0015 
 
 
Table S5. Impact of steroid therapy during ICU stay in patients with ARF. Multivariable 
analysis for factors independently associated with ICU mortality among patients with ARF. 
When adjusted on factors associated with mortality, steroid therapy was not significantly 
associated with a worse prognosis. 
 OR CI95 CI95 p.value 
  low high 
Invasive pulmonary aspergillosis 2.42 1.23 4.79 0.011 
Positive Eplex 2.05 1.21 3.48 0.0075 
Poor performance status 1.85 1.06 3.22 0.029 
SOFA score at admission 1.28 1.20 1.36 6.2e-15 
Charlson comorbidity index 1.10 0.99 1.22   0.072 
Steroid therapy during ICU stay 1.32 0.81 2.15 0.27 
 
Table S6. 
Impact of steroid therapy during ICU stay in patients with ARF and a positive viral 
detection. Multivariable analysis for factors independently associated with ICU mortality 
among patients with ARF. When adjusted on factors associated with mortality, steroid 
therapy was not significantly associated with a worse prognosis. 
 OR CI95 CI95 p.value 
  low high 
Invasive pulmonary aspergillosis 7.66 2.15 33.34 0.0031 
Poor performance status 1.43 0.52 3.91 0.48 
SOFA score at admission 1.32 1.17 1.52 3.3e-05 
Charlson comorbidity index 1.04 0.85 1.29 0.69 
Steroid therapy during ICU stay 1.03 0.41 2.63 0.95 
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Figure S1. Daily SOFA score according to the detection of any respiratory virus (A) or of 
influenza, parainfluenza, and respiratory syncytial viruses (B).  
Abbreviations: SOFA, Sequential Organ Failure Assessment; PIV, parainfluenza virus; RSV, 
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